carnitine has been researched along with Ache in 11 studies
Excerpt | Relevance | Reference |
---|---|---|
"To evaluate the therapeutic effects of L-propionyl-carnitine (LPC) in patients with critical limb ischemia (CLI), as defined by the TASC guidelines." | 9.14 | Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1. ( Genova, C; Luigi Almasio, P; Milio, G; Novo, G; Novo, S; Pinto, A, 2009) |
"Patients with cystic acne (CA) on Isotretinoin (Iso) therapy might present muscular symptoms as side effect of the drug." | 9.09 | L-carnitine supplementation in patients with cystic acne on isotretinoin therapy. ( Georgala, C; Georgala, S; Michas, T; Schulpis, KH, 1999) |
" The aim of the study was to investigate the effects of oral L-carnitine supplementation on pain (VAS scale), tenderness (pain thresholds) and CK release induced by a 20-min eccentric effort of the quadriceps muscle." | 9.08 | Effects of prolonged L-carnitine administration on delayed muscle pain and CK release after eccentric effort. ( Di Lisa, F; Dragani, L; Giamberardino, MA; Saggini, R; Valente, R; Vecchiet, L, 1996) |
"Muscle cramps are side effects commonly associated with tyrosine kinase inhibitor (TKI) treatment." | 5.43 | [Efficacy of levocarnitine for tyrosine kinase inhibitor-induced painful muscle cramps in patients with chronic myelogenous leukemia]. ( Abe, T; Fujii, S; Hamaguchi, K; Horiguchi, H; Ito, R; Kato, J; Kuroda, H; Maeda, M; Nakamura, H; Sato, K; Shimoyama, S; Sugama, Y; Yamada, M; Yamauchi, N, 2016) |
"To evaluate the therapeutic effects of L-propionyl-carnitine (LPC) in patients with critical limb ischemia (CLI), as defined by the TASC guidelines." | 5.14 | Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1. ( Genova, C; Luigi Almasio, P; Milio, G; Novo, G; Novo, S; Pinto, A, 2009) |
"Patients with cystic acne (CA) on Isotretinoin (Iso) therapy might present muscular symptoms as side effect of the drug." | 5.09 | L-carnitine supplementation in patients with cystic acne on isotretinoin therapy. ( Georgala, C; Georgala, S; Michas, T; Schulpis, KH, 1999) |
" The aim of the study was to investigate the effects of oral L-carnitine supplementation on pain (VAS scale), tenderness (pain thresholds) and CK release induced by a 20-min eccentric effort of the quadriceps muscle." | 5.08 | Effects of prolonged L-carnitine administration on delayed muscle pain and CK release after eccentric effort. ( Di Lisa, F; Dragani, L; Giamberardino, MA; Saggini, R; Valente, R; Vecchiet, L, 1996) |
"Many patients with chronic fatigue syndrome(CFS) fulfill the criteria of FMS and represent one end of a spectrum of presentation." | 2.40 | [Fibromyalgia syndrome]. ( Matsumoto, Y, 1999) |
"Muscle cramps are side effects commonly associated with tyrosine kinase inhibitor (TKI) treatment." | 1.43 | [Efficacy of levocarnitine for tyrosine kinase inhibitor-induced painful muscle cramps in patients with chronic myelogenous leukemia]. ( Abe, T; Fujii, S; Hamaguchi, K; Horiguchi, H; Ito, R; Kato, J; Kuroda, H; Maeda, M; Nakamura, H; Sato, K; Shimoyama, S; Sugama, Y; Yamada, M; Yamauchi, N, 2016) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (18.18) | 18.7374 |
1990's | 3 (27.27) | 18.2507 |
2000's | 5 (45.45) | 29.6817 |
2010's | 1 (9.09) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Yamada, M | 1 |
Kuroda, H | 1 |
Shimoyama, S | 1 |
Ito, R | 1 |
Sugama, Y | 1 |
Sato, K | 1 |
Yamauchi, N | 1 |
Horiguchi, H | 1 |
Nakamura, H | 1 |
Hamaguchi, K | 1 |
Abe, T | 1 |
Fujii, S | 1 |
Maeda, M | 1 |
Kato, J | 1 |
Milio, G | 1 |
Novo, G | 1 |
Genova, C | 1 |
Luigi Almasio, P | 1 |
Novo, S | 1 |
Pinto, A | 1 |
Boneh, A | 1 |
Baumgartner, M | 1 |
Hayman, M | 1 |
Peters, H | 1 |
Fietta, P | 1 |
Manganelli, P | 1 |
Spiering, BA | 1 |
Kraemer, WJ | 2 |
Vingren, JL | 1 |
Hatfield, DL | 1 |
Fragala, MS | 1 |
Ho, JY | 1 |
Maresh, CM | 1 |
Anderson, JM | 1 |
Volek, JS | 2 |
Giamberardino, MA | 1 |
Dragani, L | 1 |
Valente, R | 1 |
Di Lisa, F | 1 |
Saggini, R | 1 |
Vecchiet, L | 1 |
Matsumoto, Y | 1 |
Georgala, S | 1 |
Schulpis, KH | 1 |
Georgala, C | 1 |
Michas, T | 1 |
Rubin, MR | 1 |
Gómez, AL | 1 |
Ratamess, NA | 1 |
Gaynor, P | 1 |
Brand, G | 1 |
Bellmann, H | 1 |
Kothe, W | 1 |
Duck, HJ | 1 |
Rauchfuss, E | 1 |
Fleischmann, H | 1 |
Schönlebe, W | 1 |
Böhland, W | 1 |
Byrne, E | 1 |
Trounce, I | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication[NCT00822172] | Phase 4 | 164 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
Intervention | Log Minutes (Mean) |
---|---|
Cilostazol + L-Carnitine | 1.065 |
Cilostazol + Placebo | 0.896 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90
Intervention | Log Minutes (Mean) |
---|---|
Cilostazol + L-Carnitine | 1.001 |
Cilostazol + Placebo | 0.815 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
Intervention | Log Minutes (Mean) |
---|---|
Cilostazol + L-Carnitine | 0.241 |
Cilostazol + Placebo | 0.134 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
Intervention | Log Minutes (Mean) |
---|---|
Cilostazol + L-Carnitine | 0.267 |
Cilostazol + Placebo | 0.145 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90
Intervention | Log Minutes (Mean) |
---|---|
Cilostazol + L-Carnitine | 0.166 |
Cilostazol + Placebo | 0.139 |
Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 180
Intervention | score on a scale (Mean) |
---|---|
Cilostazol + L-Carnitine | 13.20 |
Cilostazol + Placebo | 6.57 |
Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 90
Intervention | score on a scale (Mean) |
---|---|
Cilostazol + L-Carnitine | 12.98 |
Cilostazol + Placebo | 10.01 |
1 review available for carnitine and Ache
Article | Year |
---|---|
[Fibromyalgia syndrome].
Topics: Biomarkers; Carnitine; Diagnosis, Differential; Fatigue; Fatigue Syndrome, Chronic; Fibromyalgia; Hu | 1999 |
5 trials available for carnitine and Ache
Article | Year |
---|---|
Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1.
Topics: Aged; Alprostadil; Cardiotonic Agents; Carnitine; Chronic Disease; Double-Blind Method; Drug Synergi | 2009 |
Responses of criterion variables to different supplemental doses of L-carnitine L-tartrate.
Topics: Adult; Analysis of Variance; Area Under Curve; Biomarkers; Blood Glucose; Carnitine; Cross-Over Stud | 2007 |
Effects of prolonged L-carnitine administration on delayed muscle pain and CK release after eccentric effort.
Topics: Adult; Analysis of Variance; Carnitine; Creatine Kinase; Humans; Male; Muscle, Skeletal; Pain; Pain | 1996 |
L-carnitine supplementation in patients with cystic acne on isotretinoin therapy.
Topics: Acne Vulgaris; Adult; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Carni | 1999 |
L-Carnitine L-tartrate supplementation favorably affects markers of recovery from exercise stress.
Topics: Adult; Biomarkers; Carnitine; Cross-Over Studies; Cytosol; Double-Blind Method; Exercise; Free Radic | 2002 |
5 other studies available for carnitine and Ache
Article | Year |
---|---|
[Efficacy of levocarnitine for tyrosine kinase inhibitor-induced painful muscle cramps in patients with chronic myelogenous leukemia].
Topics: Adult; Carnitine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Muscl | 2016 |
Methylcrotonyl-CoA carboxylase (MCC) deficiency associated with severe muscle pain and physical disability in an adult.
Topics: Adolescent; Biopsy; Carbon-Carbon Ligases; Carnitine; Diagnosis, Differential; Female; Humans; Metab | 2005 |
Carnitine: a therapeutic option for childhood psoriatic onycho-pachydermo-periostitis (POPP).
Topics: Adolescent; Arthritis, Psoriatic; Carnitine; Humans; Male; Onycholysis; Pain; Thumb; Toes; Vitamin B | 2007 |
[Administration of Hylase in Bechterew's disease].
Topics: Adult; Carnitine; Drug Synergism; Humans; Hyaluronoglucosaminidase; Injections, Intravenous; Male; P | 1975 |
Chronic fatigue and myalgia syndrome: mitochondrial and glycolytic studies in skeletal muscle.
Topics: Adult; Aged; Aged, 80 and over; Asthenia; Carnitine; Chronic Disease; Electron Transport Complex IV; | 1987 |